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Long-term outcomes of catheter ablation pulmonary
 veins on example of a clinical case patient with 
paroxysmal atrial fibrillation
INTRODUCTION
▶ Despite good progress in the management of patients with 
atrial fibrillation (AF), this arrhythmia remains one of the major 
causes of stroke, heart failure, sudden death, and 
cardiovascular morbidity in the world
▶ Since the initial description of triggers in the pulmonary veins 
that initiate paroxysmal AF, catheter ablation (CA) of AF has 
developed from a specialized, experimental procedure into a 
common treatment to prevent recurrent AF
▶ As first-line treatment for paroxysmal AF, randomized trials 
showed only modestly improved rhythm outcome with CA 
compared to antiarrhythmic drug therapy
HARRISON INTERNAL MEDICINE BOOK (18th edition; 
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RADIOFREQUENCY CATHETER 
ABLATION (RFA)  IN AF 1.2.
▶ Complete pulmonary vein 
isolation (PVI) on an atrial 
level is the best documented 
target for catheter ablation, 
achievable by point-by-point 
radiofrequency ablation, linear 
lesions encircling the 
pulmonary veins
▶ PVI was initially tested in 
patients with paroxysmal AF, 
but appears to be noninferior 
to more extensive ablation in 
persistent AF as well.
HARRISON INTERNAL MEDICINE BOOK (18th edition) 
RADIOFREQUENCY CATHETER ABLATION (RFA)  IN 
AF 2.2.
Electroanatomical 
image of the left 
atrium and 
pulmonary veins 
(posterior view) 
showing lesions 
(red circles) for 
antral pulmonary 
vein
isolation during 
catheter ablation 
of atrial fibrillation
http://www.nature.com/nrcardio/journal/v11/n5/fig_tab/nrcardio.2014.29_F1.html
CATHETER ABLATION OF PULMONARY 
VEINS VIDEO
https://www.youtube.com/watch?v=
M3BBzmhL4Fc
COMPLICATIONS RELATED TO CA OF AF
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COMBINING ANTIARRHYTHMIC DRUGS
AND CATHETER ABLATION
▶ Antiarrhythmic drug therapy is commonly given for 8–12 weeks after 
ablation to reduce early recurrences of AF after catheter ablation, 
supported by a recent controlled trial where amiodarone halved early AF 
recurrences compared with placebo
▶ Prospective studies have not been done, but a meta-analysis of the 
available (weak) evidence suggests slightly better prevention of recurrent 
AF in patients treated with antiarrhythmic drugs after catheter ablation
▶ Many patients are treated with antiarrhythmic drug therapy after catheter 
ablation (most often amiodarone or flecainide), and this seems a reasonable 
option in patients with recurrent AF after ablation
▶ The clinical case described below shows the long-term outcomes of 
CA pulmonary veins of the patient with paroxysmal atrial fibrillation
2016 ESC Guidelines for the management of atria fibrillation developed in collaboration withEACTS
OUR PATIENT 
▶ A 66 years old female (25.08.1950)
▶ Retired 
▶ Lives in Kharkiv 
▶ Admitted to our polyclinic 14/10/2016
COMPLAINTS 
▶ Dyspnea during ordinary physical 
activity, absent at rest
MEDICAL HISTORY 1.2. 
▶ 2000 - autoimmune thyroiditis III degree with nodular goiter, euthyroid state; 
right – sided thyroidectomy and isthmus resection; according patient’s report - 
euthyroidism all the time
▶ Since 2001- hypertension (max 220/110 mmHg, usual BP 150/90 mmHg (with 
drugs))
▶ 2010- paroxysmal tachycardia and palpitations, AF was first diagnosed 
▶ Since 2012 dignosis: PAROXYSMAL ATRIAL FIBRILLATION, EHRA III. 
CHA2DS2-VASc - 2. HAS-BLED score - 2. ESSENTIAL ARTERIAL 
HYPERTENSION STAGE II, 3 GRADE. HYPERTENSIVE HEART (LVH). 
HEART FAILURE WITH PRESERVED EJECTION FRACTION
▶ 2014- catheter ablation surgery of pulmonary veins 
▶ After 3 days of ablation the patient had a paroxysm of AF- an electrical 
cardioversion was performed, continued to intake prescribed anthyarritmic 
treatment for 3 months (betaxolol 10 mg/day, propafenon 300 mg/day)
MEDICAL HISTORY 2.2.
▶ Despite of drug intaking, ones in 3 weeks she had episodes of AF which were being 
stopped by intaking additional 300 mg of propafenon
▶ After 3 months  the paroxysms of AF became more infrequent (once in 3 months), 
shorter duration (1-2 hours), stopped after intaking propafenon 300 mg with 
mild/moderate symptoms of paroxysms of AF
▶ 2015 – gross hematuria on warfarin (the drug intaking was stopped); since 2015 -  
takes aspirin for prevention thromboembolic complications
▶ Following months (over 3) notes poor control of BP (increasing of it despite taking 
hypotension drugs)
▶ After 8 months to the present day of CA she started suffer from paroxysmal 
tachycardias and heart palpitations with HR 120-130 bpm with mild symptoms, which 
are not related to physical exercise (mostly at night) 1 time per month, sometimes  
related to increasement of blood pressure (BP) with duration from 1-2 min to 6 hours 
and converted to sinus rhythm by taking additional propafenon 300 mg and 
sometimes procainamide 500 mg
HISTORY OF DISEASES 
▶ 1981- appendectomy
▶ 1993 - acute pyelonephritis
▶ 2004 – radical hysterectomy, iatrogenic 
menopause
▶ 2007 - cyst in the right breast was removed
OBJECTIVE SUBJECT 1.2. 
▶ The general condition is satisfactory, consciousness is 
clear, emotionally stable, optimistic mood
▶  Hypersthenic, height 174 cm, weight 105kg, BMI = 
34.68 kg / m 2, waist-to-hip ratio 1,07
▶ Skin, visible mucous membranes are pale pink and 
clean
▶ Peripheral lymph nodes are not palpable
▶ The thyroid is not palpable in the right side, slightly in 
the left
▶ Signs of eyelid retraction, periorbital edema, proptosis 
are absent 
OBJECTIVE SUBJECT 2.2. 
▶ Respiratory System: 
pulmonary percussion –normal
auscultation - weakened vesicular breathing, no adventitious sounds
▶ Cardiovascular system: 
heart borders extended to the left on 1,5 cm of midclavicular line,  HR =78 bpm, regular.
no pulse deficiency; heart sounds are muted
▶ BP left hand = BPsin= 175/100 mmHg (on the background of antihypertensive therapy), right 
hand = BPdex= 150/90 mmHg 
▶ Gastrointestinal system:
abdomen is soft, painless, symmetrical, no discrepancies of the abdominal muscles, no 
visible peristalsis
liver  edge is smooth, painless , palpated 1.5 cm below the costal  arch 
spleen and pancreas are not palpable
▶ Symmetrical mild shin pitting edema
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▶ Blood lipid spectrum
▶ Blood electrolytes (K, Na)*
▶ TSH, T4, T3*
▶ Chest X-Ray*
▶ Ultrasound of thyroid gland*
▶ Ultrasound of abdomen*
PRESCRIBED EXAMINATIONS
▶ Complete blood test
▶  General urine test
▶ Fasting glucose level
▶  ECG
▶  EchoCG
▶  24-h ECG monitoring
▶ Biochemical blood test (liver 
(ALT, AST, AP)* and renal 
function tests (BUN*, 
creatinine), coagulogram*
*not peformed examinations due to socio-economic problems
              
Measure
      
  Result 
                    
Rate 
Hemoglobin                             137 F 120-158 g / l 
Erythrocytes                            4.52 F 4.0 – 5.2 T/L
Color index                               1.06 0.85-1.15
Leukocytes 8.3 4.0 – 9.0 g/L
ESR 10 F 2-20 mm/h
Platelets 285 160-320 g/L
Band Neutrophils                                                                    1 1-6%
COMMON BLOOD TEST (16/10/2016) 
          
Measure
           
Result Rate 
Segmented 
Neutrophils          
59 47-72 %
Eosinophils                                  2 0.5-5.0% 
Basophils                                           0 1-1.0 %
Monocytes                                                                              4 3-11%
Lymphocytes 33 19-37%
Hematocrit                                   39 F  35-44 % 
Conclusion : normal  
GENERAL URINE TEST (16/10/16) 
Conclusion: normal  
           MEASURE         RESULT NORMAL RANGE 
SPECIFIC GRAVITY 1.014 1.001-1.040
REACTION 6.4 5.0-7.0
PROTEIN 0.021  to 0.033 g / l 
GLUCOSE Absent Absent
LEUCOCYTES                             2-3 6-8
EPITHELIUM 
TRANSITION    
Not detected Not detected 
BACTERIA                                 Not detected Not detected 
BIOCHEMICAL BLOOD TEST (16/10/16)
MEASURE RESULT NORMAL RANGE 
Creatinine 92 53-123 mcmol/L
Conclusion: normal
ESTIMATED GFR NORMAL RANGE 
The Modification of Diet in 
Renal Disease (MDRD) 
Study equation 
54 ml/min/1.73 m2 Age (60–69) - 85 ml/min/1.73 m2
GFR (mL/min/1.73 m2) = 175 × (Scr)
-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African 
American)
Conclusion: decreased  kidney function 
https://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/lab-evaluation/gfr/estimating/Pages/estimating.aspx
FASTING GLUCOSE TEST (16/10/16)
RESULT NORMAL RANGE 
5.4 4.2-6.1 mmol/l
Conclusion: normal
THYROID-STIMULATING HORMONE (TSH) 
(16/10/16)
RESULT NORMAL RANGE 
3.2  0.4-4.0 mlU/L
Conclusion: normal
BLOOD LIPID SPECTRUM (16/10/16)
MEASURE RESULT RATE 
TOTAL 
CHOLESTEROL
7.34 ≤ 5.2 mmol / l 
VLDL 0.97 <1.0 mmol / l 
LDL 5.29 <3.5 mmol / l 
HDL- cholesterol 
levels
1.08 >0.9 mmol / l 
Triglycerides 2.12 ≤2.3 mmol / l 
COEFFICIENT of 
atherogenicity 
5.8 To 3.0 mmol/l 
Conclusion: dyslipidemia 
http://eurheartj.oxfordjournals.org/content/ehj/34/39/3035.full.pdf
 ECG with paroxysm of AF before CA 
Conclusion: paroxysm of AF with HR 115-125 bpm
 ECG with paroxysm of AF 2 years 
after CA 
Conclusion: paroxysm of AF with HR 90-110 bpm. Violation of the repolarization 
processes on the left ventricular posterior wall (also artifacts on the ECG)
 ECG 2 years after CA 
Conclusion: sinus rhytm, regular, heart rate 78bpm , signs of left ventricular 
hypertrophy 
24-h AMBULATORY ECG MONITORING 2 
YEARS AFTER CA 1.2.
 Conclusion : 
▶ During the monitoring 22 h 38 min  was registered sinus rhythm 
with a mean heart rate 74 bpm (maximum HR 120 pm, at 
20:05:15, minimum HR 66 bpm - 16:50:55)
▶ Was recorded: single supraventricular premature contractions 
(total 266); single monomorphic ventricular premature 
contractions (total 49); short episodes of supraventricular 
tachyarrhythmias (total 4) with an average heart rate of 160 bpm 
with max duration for up to 5 seconds
▶ Ischemic changes have not been identified
▶ Circadian index  1.07 (N 1.24-1.44)
24-h AMBULATORY ECG MONITORING 2 YEARS 
AFTER CA 2.2. :
 Episodes of short supraventricular tachyarrhythmia
HEART RATE VARIABILITY 2 YEARS AFTER CA
Conclusion:
▶ This character of the rhythmogram and HRV 
indicates the structure to stabilize the heart 
rhythm with the transition of its regulation 
from  the reflex autonomic level to a lower 
humoral-metabolic, are not able to quickly 
provide homeostasis
▶ Functional heart capabilities are reduced
▶ Condition of a poor adaptation with a sharp 
decline in the functional capacity of the body
ECHOCARDIOGRAPHY 1.2.
Name Result
before ablation
Result
2 years after 
ablation
Normal
1) Acoustic window normal normal normal
2) Aorta 34 34 20-37 mm
3) Aortic Valve 17.5 16 17-26 mm
4) Left Atrium 44 42 To  38 mm
5) Mitral Valve Regurgitation I degree Regurgitation I degree
6)Posterior wall of 
the LV 
13 12 6-11 mm
7) Interventricular 
septum
13 12 6-11 mm
8) Right Ventricle 26 26 D.: (9-26 mm) 
ECHOCARDIOGRAPHY 2.2.
Name Result
before ablation
Result
2 years after 
ablation
Normal
9) Right Atrium 35 35 <38 mm
10) Tricuspid Valve
11) Ejection Fraction 52 57 55-78%
Conclusion 2 years after ablation: Atherosclerosis of aorta and 
aortic valves mild degree. Moderate dilatation of left atrium. 
Concentric left ventricle hypertrophy (LV Mass Index 100 g/m2. 
RWT 0.49). Dyssynergic areas were not identified. Diastolic 
function - relaxation violation (E/A-0.8)
BASIC CLINICAL SYNDROMES
▶ Atherosclerosis (sclerotic changes of aorta and aortic valve) 
▶ Arterial hypertension
▶ Arrhythmias (paroxysmal AF)
▶ Reduction of circadian index and heart spectrum, as a 
manifestation of reducing humoral and autonomic regulation 
with non-dipper HR
▶ Heart failure
▶ Dyslipidemia
▶ Hypertensive  heart (LVH, atrial enlargement, diastolic 
dysfunction)
▶ Obesity
The clinical diagnosis 
according 
to current classifications
TYPES OF AF ACCORDING GUIDELINES 
AF pattern Definition
First diagnosed AF
AF that has not been diagnosed before, irrespective of the duration 
of the arrhythmia or the presence and severity of AF-related 
symptoms.
Paroxysmal AF
Self-terminating, in most cases within 48 hours. Some AF paroxysms 
may continue for up to 7 days. AF episodes that are cardioverted 
within 7 days should be considered paroxysmal.
Persistent AF
AF that lasts longer than 7 days, including episodes that are 
terminated by cardioversion, either with drugs or by direct current 
cardioversion, after 7 days or more.
Long-standing
persistent AF
Continuous AF lasting for ≥1 year when it is decided
to adopt a rhythm control strategy.
Permanent AF
AF that is accepted by the patient (and physician). Hence, rhythm 
control interventions are, by AF. Should a rhythm control strategy be 
adopted, the
arrhythmia would be re-classified as ‘long-standing definition, not 
pursued in patients with permanent persistent AF’.
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MODIFIED EUROPEAN HEART RHYTHM ASSOCIATION 
SYMPTOM SCALE (MODIFIED FROM WYNN ET AL)
2016 ESC Guidelines for the management of atrial fibrillation developed  in collaboration withEACTS
CHA2-DS2-VASC RATING SCALE RISK OF THROMBOEMBOLIC 
COMPLICATIONS IN PATIENTS WITH ATRIALFIBRILLATION / FLUTTER 
                               RISK FACTOR        POINTS
C Congestive heart failure/left ventricular dysfunction 1
H Hypertension 1
A2 Age ≥75 years 2
D Diabetes mellitus 1
S2 Stroke/transient ischaemic attack/thromboembolism 2
V
Vascular disease (prior myocardial infarction, 
peripheral artery disease, aortic plaque) 1
A Age 65–74 years 1
SC Sex category (i.e. female gender) 1
Conclusion: total points 5. The expected frequency of strokes per year  6.7%
www.thrombosisadviser.com/en/atrial-fibrillation/af-is-a-major-stroke-risk-factor
SCALE HAS-BLED: RISK FACTORS FOR BLEEDING 
(ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION, 2011) 
Condition Points 
 H  Hypertension: (uncontrolled, >160 mmHg systolic) 1
 A
 Abnormal renal function: dialysis, transplant, Cr >2.6 mg/dL or >200 
µmol/L Abnormal liver function: Cirrhosis or Bilirubin >2x Normal or 
AST/ALT/AP >3x Normal
1
 S  Stroke: Prior history of stroke 1
 B  Bleeding: Prior Major Bleeding or Predisposition to Bleeding 1
 L  Labile INR: (Unstable/high INRs), Time in Therapeutic Range < 60% 1
 E  Elderly: Age > 65 years Medication 1
 D  Prior Alcohol or Drug Usage History (Antiplatelet agents, NSAIDs) 1 
Conclusion: HAS-BLED score- 4. The patient has a HIGH risk of bleeding. The risk of major 
bleeding within 1 year in patients with atrial expressed as bleeds per 100 patient years: 3.76 – 
6.4% 
http://www.globalrph.com/has-bled-score.cgi
CLASSIFICATION OF OFFICE 
BLOOD PRESSURE LEVELS (MMHG)
Category Systolic Diastolic
Optimal <120 and <80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 
hypertension
140–159 and/or 90–99
Grade 2 
hypertension
160–179 and/or 100–109
Grade 3 
hypertension
>/=180 and/or >/=110
Isolated systolic 
hypertension
>/=140 and <90
http://emedicine.medscape.com/article/241381-overview
CLASSIFICATION OF HYPERTENSION STAGES (RECOMMENDATIONS OF 
THE ASSOCIATION OF CARDIOLOGISTS OF UKRAINE 2008)
Stage The degree of target organ damage
I Objective changes in the target organs are absent
II There is objective evidence of target organ damage without symptoms with their 
hand or dysfunction:Left ventricular hypertrophy (on ECG, ultrasound, Ro) 
Generalized narrowing of retinal arteries Microalbuminuria and / or a small increase 
in serum creatinine (y m. - 115 - 133 mmol / L at x. -107 - 124 mmol / l) Carotid 
artery disease - a thickening of the intima-media> 0.9 mm or the presence of 
atherosclerotic plaques.
III There is objective evidence of target organ damage with symptoms from their side 
and impaired heart - myocardial infarction, heart failure II A - III stage; 
brain - stroke, transient ischemic attack, acute hypertensive encephalopathy, 
vascular dementia; fundus - hemorrhage and retinal exudates with papilledema the 
optic nerve or without; 
kidney - concentration of plasma creatinine in males> 133 umol / L, y Women> 124; 
vessels - dissecting aortic aneurysm; peripheral arterial occlusion
http://www.mif-ua.com/education/symposium/arterialnaya-gipertenziya-v-2014-g-klassifikacii-diagnostika-lechenie#test_end
THE NEW YORK HEART ASSOCIATION (NYHA) 
FUNCTIONAL CLASSIFICATION (FUNCTIONAL CAPACITY) 
OF CHRONIC HEART FAILURE
http://www.intechopen.com/books/primary-care-in-practice-integration-is-needed/integrated-care-for-heart-failure-in-primary-care
AMERICAN HEART ASSOCIATION 
HEART FAILURE STAGES
Class Objective Assessment
A No objective evidence of cardiovascular disease. No symptoms and no 
limitation in  ordinary physical activity.
B Slight limitation of physical activity. Comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, dyspnea (shortness of breath).
C Objective evidence of moderately severe cardiovascular disease. Marked 
limitation in activity due to symptoms, even during less-than-ordinary activity. 
Comfortable only at rest.
D Objective evidence of severe cardiovascular disease. Severe limitations. 
Experiences  symptoms even while at rest.
http://www.sunshineheart.com/patients/classification-of-heart-failure
DEFINITION OF HEART FAILURE WITH PRESERVED (HFpEF), 
MID-RANGE (HFmrEF) AND REDUCED EJECTION FRACTION 
(HFrEF)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
CARDIOVASCULAR RISK STRATIFICATION CHART WITH 
RECOMMENDED FOLLOW-UP FREQUENCY FOR EACH 
CATEGORY
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
LIPOPROTEIN PATTERNS 
(FREDRICKSON PHENOTYPES)
Phenotype Elevated Lipoprotein(s) Elevated Lipids
I Chylomicrons TGs
IIa LDL Cholesterol
IIb LDL and VLDL TGs and cholesterol
III VLDL and chylomicron 
remnants
TGs and cholesterol
IV VLDL TGs
V Chylomicrons and VLDL TGs and cholesterol
http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia
LDL = low-density lipoprotein; TGs = triglycerides; VLDL = very-low-density lipoprotein
https://www.google.com.ua/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0ahUKEwjF56uN4r_QAhXGVSwKHTfmDl4QFggrMAI&url=http%3A%2F%2Fghsrenal.com%2Fckd%2FH
FHS_CKD_GUIDELINES_V7.0.pdf&usg=AFQjCNE5Ww6O5G9DQnR28wwTya1LSQT0GQ&sig2=CXDpmnnTBG51p4Wq6cqK4w&cad=rja
CLASSIFICATION OF CHRONIC KIDNEY DISEASE 
(CKD STAGES)
http://nutritionfirstfitness.com/tools.php?tool=waisttohip
WAIST TO HIP RATIO
CLASSIFICATION OF OVERWEIGHT 
AND OBESITY BMI CLASSIFICATION 
Classification BMI Category 
(kg/m2)
Risk of developing 
health problems
Underweight < 18.5 Increased
Normal Weight 18.5 - 24.9 Least
Overweight 25.0 - 29.9 Increased
Obese class I 30.0 - 34.9 High
Obese class II 35.0 - 39.9 Very high
Obese class III >= 40.0 Extremely high
http://www.hc-sc.gc.ca/fn-an/nutrition/weights-poids/guide-ld-adult/bmi_chart_java-graph_imc_java-eng.php
COMPLETE MAIN DIAGNOSIS OF OUR PATIENT
Diagnosis before  ablation
▶ PAROXISMAL ATRIAL 
FIBRILLATION, EHRA III
▶ CHA2DS2-VAS score - 2
▶ HAS-BLED score - 2
▶ ESSENTIAL ARTERIAL 
HYPERTENSION STAGE II,3 
GRADE
▶ HYPERTENSIVE HEART (LVH)
▶ HEART FAILURE WITH 
PRESERVED EJECTION 
FRACTION
Diagnosis 2 years after ablation
▶ CONDITION AFTER CA OF PULMONARY VEINS DUE TO 
PAROXYSMAL AF (25/04/14), WITH DECREASEMENT IN 
FREQUENCY OF PAROXYSMS FROM ONES IN 3 WEEKS TO ONES 
PER 2 MONTHS.
▶ CHA2DS2-VAS score - 5
▶ HAS-BLED score - 4
▶ ESSENTIAL ARTERIAL HYPERTENSION STAGE II,3 GRADE
▶ HYPERTENSIVE HEART (LVH)
▶ HEART FAILURE WITH PRESERVED EJECTION FRACTION II FC,  
STAGE B
▶ SYSTEMIC ATHEROSCLEROSIS (ATHEROSCLEROSIS OF THE 
AORTA AND AORTIC VALVES, DYSLIPIDEMIA II A  TYPE AFTER 
FREDRICKSON)
▶ VERY HIGH ADDED TOTAL CV RISK
▶ AUTOIMMUNE THYROIDITIS (FOCAL? Riedel's? Hashimoto's?) 
▶ CONDITION AFTER RIGHT – SIDED THYROIDECTOMY AND 
ISTHMUS RESECTION (2000), EUTHYROID
▶ DEEP DECLINE THE POWER OF ALL BRANCHES AUTONOMIC 
REGULATION: NON-DIPPER HR WITH LOW DEGREE OF TP
CO-MORBIDITY OF OUR PATIENT
2 years after ablation
▶ CKD 3A: HYPERTENSIVE NEPHROPATHY (eGFR 54 
ML/MIN/1.73 m2)
▶ OBESITY I CLASS
▶ NON-ALCOHOLIC FATTY LIVER DISEASE?
TREATMENT
GOAL-BASED FOLLOW-UP
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
LIFESTYLE MODIFICATION
▶Intensive weight reduction in addition to the 
management of other cardiovascular risk 
factors (in the range of 10–15 kg weight loss 
achieved), led to fewer AF recurrences and 
symptoms compared with an approach based 
on general advice in obese patients with AF
▶DASH diet
▶Control of compliance to medical 
recommendations
http://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/dash-diet/art-20048456
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
STROKE PREVENTION IN AF
ANTICOAGULATION AFTER SUCCESSFUL’
CATHETER ABLATION
▶ In view of the long-term recurrence rates of AFaccording 2016 
guidlines OAC is recommended to continue in AF patients after 
‘successful’ catheter ablation
▶ Nonetheless, observational data suggest that the stroke risk may 
be lower after catheter ablation of AF compared with other AF 
patients
▶ The ongoing EAST – AFNET 4 trial will inform, in a more general 
way, whether rhythm control therapy can reduce stroke rates in 
anticoagulated AF patients
▶  In addition, there seems to be a place for a controlled trial 
evaluating the termination of OAC therapy at an interval after 
‘successful’ catheter ablation
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
AF AND HYPERTENSION
▶ Secondary analyses of trials in patients with 
LVH and hypertension have found that 
angiotensin receptor blockers (ARBs) 
(losartan, valsartan) are better in preventing 
first occurrence of atrial fibrillation than 
beta-blocker (atenolol) or calcium 
antagonist (amlodipine) therapy, consistent 
with similar analyses in patients with heart 
failure
2013 ESH/ESC Guidelines for themanagement of arterial hypertension
SUMMARY OF RECOMMENDATIONS ON THERAPEUTIC 
STRATEGIES IN HYPERTENSIVE PATIENTS WITH HEART 
DISEASE 1.2.
2013 ESH/ESC Guidelines for themanagement of arterial hypertension
SUMMARY OF RECOMMENDATIONS ON THERAPEUTIC 
STRATEGIES IN HYPERTENSIVE PATIENTS WITH HEART 
DISEASE 2.2.
2013 ESH/ESC Guidelines for themanagement of arterial hypertension
ORAL ANTIARRYTHMIC DRUGS USED FOR MAINTANING SINUS RHYTHM
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
PATIENT’S MEDICAL TREATMENT 
FOR LAST 6 MONTH
▶ Bisoprolol 5 mg per day
▶ Propafenon 150 mg 2 times per day (without this 
drug –recurrence of AF paroxysms); episodically 
additionally 300 with/without procainamide 500 mg
▶ Valsartan 80 mg per day
▶ Atorvastatin 10 mg  (do not intake regularly)
▶ Aspirin 75 mg per day
OUR RECOMMENDED TREATMENT  
▶ Β- blocker - CARVEDILOL 12,5 mg  2 times p/day under control 
of ECG
▶ AAD – PROPAFENONE 150 mg 3 times per day under control of 
ECG; additional 300 mg of propafenon in case of paroxysm of AF
▶ ARBs – VALSARTAN 160 mg in the morning
▶ Anticoagulant - RIVAROXABAN  15 mg p/day 
▶ Statin-ROSUVASTATIN  20 mg in the evening 
▶ Consulting with other subspecials to change treatment strategy 
(repeat catheter ablation?)
ADDITIONAL RECOMMENDED  
EXAMINATIONS
▶ Repeat 24h – ECG monitoring in a month 
▶ T4, T3, Anti-TPO
▶ Biochemical blood test (liver (ALT, AST, AP) and renal function tests 
(BUN), coagulogram
▶ Blood electrolytes (K, Na)
▶ Chest X-Ray
▶ Ultrasound of thyroid gland and abdomen
▶ Сonsultation with an endocrinologist
PROGNOSIS
▶ Prognosis for life - non-compliance to 
doctor's appointments – non-satisfactory 
▶ The prognosis for recovery - an 
unfavorable
CONCLUSION 1.2.
▶According to recent studies it has been demonstrated that pulmonary vein CA has 
favourable outcomes at 6-12 months post-ablation, but there are only few studies with a 
long-term follow-up and, as we see on our clinical case, after 2 years patient present with 
current deterioration of AF
▶The vast majority of very longstanding paroxysmal/persistent AF patients maintained 
sinus rhythm at a mean follow-up time of 5 years following CA, associated with a 
significant improvement in symptom scores and, as we see on our clinical case, after 2 
years patient maintained sinus rhythm, but with recurrence paroxysms of AF for last year 
with mild/moderate of symptom scores
▶Often this procedure is not a radical solution of the problem, and most patients (as it also 
was shown on the example of our clinical case) are require adjunctive therapies including 
antiarrhythmics, DC cardioversions and re-ablation
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
https://www.ncbi.nlm.nih.gov/pubmed/27878420, https://www.ncbi.nlm.nih.gov/pubmed/27889553, 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1431605/
CONCLUSION 2.2. 
▶Also our patient needs correction of the treatment of arterial hypertension and more 
properly diagnosis (and treatment) of thyroid disorder, and improvement the 
regulation at all levels - from the daily rhythm of the HR up to relations in the activity 
of the vagal activity branches, first of all, interventions in the lifestyle and searching for 
the optimum time drug administration 
▶Of course, consider the presence of multiple syndromes on presented clinical case, 
we must not forget about the problem of polypharmacy and try to avoid it (many 
studies in ambulatory care define polypharmacy as a medication count of five or more 
medications, but it is practically impossible to investigate the biochemical compatibility 
in vivo of more than 4 drugs)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
https://www.ncbi.nlm.nih.gov/pubmed/27878420, https://www.ncbi.nlm.nih.gov/pubmed/27889553, 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1431605/
THANK YOU FOR ATTENTION!
